328 related articles for article (PubMed ID: 36768798)
1. The Interplay between α-Synuclein and Microglia in α-Synucleinopathies.
Deyell JS; Sriparna M; Ying M; Mao X
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768798
[TBL] [Abstract][Full Text] [Related]
2. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
Miao Y; Meng H
Cell Commun Signal; 2024 Jan; 22(1):31. PubMed ID: 38216911
[TBL] [Abstract][Full Text] [Related]
3. Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells.
Kim C; Kwon S; Iba M; Spencer B; Rockenstein E; Mante M; Adame A; Shin SJ; Fields JA; Rissman RA; Lee SJ; Masliah E
Exp Mol Med; 2021 Feb; 53(2):281-290. PubMed ID: 33594256
[TBL] [Abstract][Full Text] [Related]
4. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
6. MerTK is a mediator of alpha-synuclein fibril uptake by human microglia.
Dorion MF; Yaqubi M; Senkevich K; Kieran NW; MacDonald A; Chen CXQ; Luo W; Wallis A; Shlaifer I; Hall JA; Dudley RWR; Glass IA; ; Stratton JA; Fon EA; Bartels T; Antel JP; Gan-Or Z; Durcan TM; Healy LM
Brain; 2024 Feb; 147(2):427-443. PubMed ID: 37671615
[TBL] [Abstract][Full Text] [Related]
7. Loss of cannabinoid receptor 2 promotes α-Synuclein-induced microglial synaptic pruning in nucleus accumbens by modulating the pCREB-c-Fos signaling pathway and complement system.
Feng L; Lo H; You H; Wu W; Cheng X; Xin J; Ye Z; Chen X; Pan X
Exp Neurol; 2023 Jan; 359():114230. PubMed ID: 36162511
[TBL] [Abstract][Full Text] [Related]
8. Neurons and Glia Interplay in α-Synucleinopathies.
Mavroeidi P; Xilouri M
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066733
[TBL] [Abstract][Full Text] [Related]
9. Epothilone D inhibits microglia-mediated spread of alpha-synuclein aggregates.
Valdinocci D; Grant GD; Dickson TC; Pountney DL
Mol Cell Neurosci; 2018 Jun; 89():80-94. PubMed ID: 29673913
[TBL] [Abstract][Full Text] [Related]
10. Alpha Synuclein: Neurodegeneration and Inflammation.
Forloni G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982988
[TBL] [Abstract][Full Text] [Related]
11. FcγRIIB mediates the inhibitory effect of aggregated α-synuclein on microglial phagocytosis.
Choi YR; Kang SJ; Kim JM; Lee SJ; Jou I; Joe EH; Park SM
Neurobiol Dis; 2015 Nov; 83():90-9. PubMed ID: 26342897
[TBL] [Abstract][Full Text] [Related]
12. Transmission of α-synuclein seeds in neurodegenerative disease: recent developments.
Karpowicz RJ; Trojanowski JQ; Lee VM
Lab Invest; 2019 Jul; 99(7):971-981. PubMed ID: 30760864
[TBL] [Abstract][Full Text] [Related]
13. An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels.
Serratos IN; Hernández-Pérez E; Campos C; Aschner M; Santamaría A
Mol Neurobiol; 2022 Jan; 59(1):620-642. PubMed ID: 34750787
[TBL] [Abstract][Full Text] [Related]
14. Synucleinopathies: Intrinsic and Extrinsic Factors.
Lomeli-Lepe AK; Castañeda-Cabral JL; López-Pérez SJ
Cell Biochem Biophys; 2023 Sep; 81(3):427-442. PubMed ID: 37526884
[TBL] [Abstract][Full Text] [Related]
15. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies.
Kim C; Beilina A; Smith N; Li Y; Kim M; Kumaran R; Kaganovich A; Mamais A; Adame A; Iba M; Kwon S; Lee WJ; Shin SJ; Rissman RA; You S; Lee SJ; Singleton AB; Cookson MR; Masliah E
Sci Transl Med; 2020 Oct; 12(565):. PubMed ID: 33055242
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation.
Chavarría C; Ivagnes R; Souza JM
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625583
[TBL] [Abstract][Full Text] [Related]
18. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
[TBL] [Abstract][Full Text] [Related]
19. Sleep-controlling neurons are sensitive and vulnerable to multiple forms of α-synuclein: implications for the early appearance of sleeping disorders in α-synucleinopathies.
Dos Santos AB; Skaanning LK; Thaneshwaran S; Mikkelsen E; Romero-Leguizamón CR; Skamris T; Kristensen MP; Langkilde AE; Kohlmeier KA
Cell Mol Life Sci; 2022 Jul; 79(8):450. PubMed ID: 35882665
[TBL] [Abstract][Full Text] [Related]
20. Systemic inflammation activates coagulation and immune cell infiltration pathways in brains with propagating α-synuclein fibril aggregates.
Laursen AS; Olesen MV; Folke J; Brudek T; Knecht LH; Sotty F; Lambertsen KL; Fog K; Dalgaard LT; Aznar S
Mol Cell Neurosci; 2024 Jun; 129():103931. PubMed ID: 38508542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
